GH Guardant Health, Inc. Loading...

From DGX earnings calls
Loading chart...
Top Calls
Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
0 selected
All Content✓
Source feeds
Buzzberg Top 50 ✓
All market capsNo capitalization filter✓
200 B and aboveMega✓
10 B to 200 BLarge✓
2 B to 10 BMid✓
0 to 2 BSmall✓
Custom
Enter market cap range in B USD
All directions✓
▲ Long✓
▼ Short✓
⛔ Avoid✓
✂ Close✓
◦ Others✓
Any score✓
LOW+✓
MED+✓
HIGH✓
08:30
Jul 23 ◎
Jim Davis Chairman, CEO and President, Quest Diagnostics Incorporated DGX Q2 FY26 call
Quest serves as a collection and testing partner for Guardant's Shield colon cancer screening test, but management declined to disclose volumes.
GH
HIGH
08:30
Apr 21 ◎
Jim Davis Chairman, Chief Executive Officer and President, Quest Diag… DGX Q1 FY26 call
Quest will collect blood samples for Guardant's colon cancer test and list it on their menu; early adoption is underway but volumes are not yet material.
GH
HIGH
08:30
Feb 10 ◎
Jim Davis Chairman, CEO and President, Quest Diagnostics Incorporated DGX Q4 FY25 call
Quest will provide draw services for Guardant's colon cancer blood test, potentially expanding Quest's consumer and oncology volume.
GH
HIGH
08:30
Oct 21 ◎
Jim Davis President and CEO, Quest Diagnostics Incorporated DGX Q3 FY25 call
Quest is distributing Guardant's colorectal cancer screening test, expanding Guardant's reach into primary care.
GH
HIGH

About GH Analyst Coverage

Buzzberg tracks GH (Guardant Health, Inc.) across 1 sources. 0 bullish vs 0 bearish calls from 1 analysts. Sentiment: evenly split. 4 total trade ideas tracked. Latest voices: Jim Davis.